CELLECT BIOTECH/S (APOP) Hits New 52-Week Low at $0.93
CELLECT BIOTECH/S (NASDAQ:APOP) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $0.93 and last traded at $0.97, with a volume of 216013 shares traded. The stock had previously closed at $0.95.
APOP has been the subject of several recent analyst reports. Zacks Investment Research raised CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Thursday, January 3rd. HC Wainwright set a $12.00 price objective on CELLECT BIOTECH/S and gave the company a “buy” rating in a research note on Wednesday, December 12th.
The company has a market cap of $5.30 million, a price-to-earnings ratio of -1.18 and a beta of 2.43.
An institutional investor recently bought a new position in CELLECT BIOTECH/S stock. Susquehanna International Group Ltd. acquired a new stake in CELLECT BIOTECH/S (NASDAQ:APOP) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,964 shares of the company’s stock, valued at approximately $25,000. CELLECT BIOTECH/S makes up about 0.0% of Susquehanna International Group Ltd.’s holdings, making the stock its 28th biggest position. Susquehanna International Group Ltd. owned 0.22% of CELLECT BIOTECH/S as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 2.57% of the company’s stock.
WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/cellect-biotech-s-apop-hits-new-52-week-low-at-0-93/2919451.html.
CELLECT BIOTECH/S Company Profile (NASDAQ:APOP)
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Featured Story: Options Trading – What is a Straddle?
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.